The N-methyl-D-aspartate receptor and schizophrenia

R. D. Strous, D. C. Javitt*

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review


Many patients with schizophrenia respond relatively rapidly to low doses of dopamine antagonists and, thus, conform well to the predictions of the dopamine hypothesis. Other patients, however, respond only slowly and partially even to high doses. For such patients, alternate models are required. The phencyclidine/N-methyl-D-asparate (PCP/NDMA) model, while still under development, offers an alternative view of brain function in schizophrenia and a framework for development of new treatments. Medications augmented with NDMA receptors are already showing clinical promise. Future developments in this area may permit the development of even more specific diagnosis and therapeutic interventions.

Original languageEnglish
Pages (from-to)275-281
Number of pages7
JournalIsrael Journal of Medical Sciences
Issue number5
StatePublished - May 1996
Externally publishedYes


  • Glycine
  • N-methyl-D-aspartate
  • Negative symptoms
  • Phencyclidine
  • Schizophrenia


Dive into the research topics of 'The N-methyl-D-aspartate receptor and schizophrenia'. Together they form a unique fingerprint.

Cite this